• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Jevtana (cabazitaxel)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Jevtana (cabazitaxel)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Jevtana (cabazitaxel) is an orally bioavailable taxane anti-neoplastic agent. It works by disrupting the microtubular network that is essential for mitotic and interphase cellular functions and causes inhibition of cell division and cell death. Cabazitaxel has been shown to inhibit cell division and tumor cell proliferation by binding to and stabilizing tubulin, a protein in the microtubules of cells which provides a skeleton for maintaining cell shape.

    Jevtana is specifically indicated in combination with prednisone for the treatment of metastatic hormone refractory prostate cancer in patients previously treated with a docetaxel-containing treatment regimen.

    Jevtana is supplied as a solution for intravenous administration. Patients should be premedicated at least 30 minutes prior to each dose of Jevtana with the following intravenous medications to reduce the risk and/or severity of hypersensitivity: antihistamine, corticosteroid or H2 antagonist. The individual dosage of Jevatana is based on calculation of the Body Surface Area and is 25 mg/m2 administered as a one-hour intravenous infusion every three weeks in combination with oral prednisone 10 mg administered daily throughout Jevtana treatment. The Jevtana dose should be reduced to 20 mg/m2 if one of the following adverse reactions occurs: prolonged grade >3 neutropenia for more than one week despite medication; febrile neutropenia or Grade >3 diarrhea or persisting diarrhea despite appropriate medication. Jevtana should be discontinued if a patient continues to experience any of these reactions at 20 mg/m2.

    Clinical Results

    FDA Approval
    The FDA approval of Jevtana was based on a randomized, open-label, international, multi-center study. The trial enrolled a total of 755 patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. The subjects received either Jevtana 25 mg/m2 intravenously every 3 weeks for a maximum of 10 cycles with prednisone 10 mg orally daily or mitoxantrone 12 mg/m2 intravenously every 3 weeks for 10 cycles with prednisone 10 mg orally daily for a maximum of 10 cycles. In the Jevtana + prednisone arm there were 61.9 % deaths while there were 74% deaths in the mitoxantrone + prednisone arm. The median survival was 15.1 months in the Jevtana + prenisone arm and 12.7 months in the mitoxantrone + prednisone arm. Investigator-assessed tumor response of 14.4% was higher for patients in the Jevtana arm compared to 4.4% for patients in the mitoxantrone arm (p=0.0005).

    Side Effects

    Adverse events associated with the use of Jevtana may include, but are not limited to, the following:

    • Anemia
    • Leukopenia
    • Neutropenia
    • Thrombocytopenia
    • Diarrhea
    • Fatigue
    • Nausea
    • Vomiting
    • Constipation
    • Asthenia
    • Abdominal pain
    • Hematuria
    • Back pain
    • Anorexia
    • Peripheral neuropathy
    • Pyrexia
    • Dyspnea
    • Dysguesia
    • Cough
    • Arthralgia
    • Alopecia

    Mechanism of Action

    Cabazitaxel is an orally bioavailable taxane anti-neoplastic agent. It works by disrupting the microtubular network that is essential for mitotic and interphase cellular functions and causes inhibition of cell division and cell death. Cabazitaxel has been shown to inhibit cell division and tumor cell proliferation by binding to and stabilizing tubulin, a protein in the microtubules of cells which provides a skeleton for maintaining cell shape.

    Additional Information

    For additional information regarding Jevtana or prostate cancer, please visit the sanofi aventis web page.

    Approval Date: 2010-06-01
    Company Name: sanofi aventis
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Virtual Doctoer

      Simple Changes Can Make Trials More Patient Friendly

    • Drug approval

      Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

    • VaccinewithNeedle-360x240.png

      Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

    • AskTheExperts-360x240.png

      Ask the Experts: Trial Operations Adjustments in a Remote World

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing